Rituxan Patent Survives Celltrion, Pfizer PTAB Challenges

Law360 (February 22, 2018, 7:26 PM EST) -- The Patent Trial and Appeal Board on Wednesday upheld the validity of a patent covering Biogen Inc. and Genentech Inc.’s rheumatoid arthritis biologic Rituxan, shooting down combined challenges from Celltrion Inc. and Pfizer Inc.

The challenge to U.S. Patent No. 7,820,161 B1 was doomed by Celltrion and Pfizer’s inability to prove one of the main pieces of prior art they relied on was public before the patent was granted, the PTAB said. Then the duo failed to prove that a combination of other pieces of prior...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.